Incyte Genomics Inc (INCY) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with N...
Incyte Genomics Inc's revenue increased 21.2% year over year, from $4.24B to $5.14B.
Net income increased 3845.0% over the same period, from $32.6M to $1.29B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 365% in total.
Operating cash flow grew 321.5% to $1.41B.
Incyte Genomics Inc maintains a strong net profit margin of 25.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.14B+9.0% | $106.5M | $2.61B | $112.8M | $310.9M | $5.01B | $36.5M | $3.17B |
| Q4 FY2024 | $1.18B+3.6% | $201.2M | $1.09B | $301.5M | $381.2M | $5.44B | N/A | $3.45B |
| Q1 FY2025 | $1.05B-10.7% | $158.2M | $979.7M | $205.2M | $266.1M | $5.75B | $43.1M | $3.67B |
| Q2 FY2025 | $1.22B+15.4% | $405.0M | $1.14B | $530.3M | $44.7M | $5.82B | $42.4M | $4.17B |
| Q3 FY2025 | $1.37B+12.4% | $424.2M | $1.27B | $443.5M | $559.4M | $6.33B | $41.3M | $4.65B |
| Q4 FY2025 | $1.51B+10.3% | $299.3M | $1.39B | $335.9M | $543.3M | $6.96B | N/A | $5.17B |
| Q1 FY2026 | $1.27B-15.5% | $303.3M | $1.17B | $301.1M | $369.4M | $7.34B | $39.4M | $5.62B |
| Q2 FY2026 | $1.67B+31.5% | $585.6M | $1.57B | $697.9M | $507.7M | $7.87B | $38.3M | $6.34B |
Balance Sheet Summary (Q2 FY2026)
Incyte Genomics Inc (INCY) Financial Statements & Revenue History
Incyte Genomics Inc (INCY) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry trading at $113.07 with a market capitalization of $23. This page provides 40 historical financial statements for Incyte Genomics Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Incyte Genomics Inc reported revenue of $5.1 billion, representing 21.2% year-over-year growth. The net profit margin of 25.0% reflects strong profitability..
INCY Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Incyte Genomics Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether INCY is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track INCY's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Incyte Genomics Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of INCY's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use INCY Financial Data
Investors use Incyte Genomics Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare INCY's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how INCY's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View INCY's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Incyte Genomics Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.INCY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.